RESUMEN
Aim: The present study was undertaken to evaluate the performance of different algorithms for flattening filter-free (FFF) and flattened (FF) photon beams in three different in-homogeneities. Materials and Method: Computed tomography (CT) image sets of the CIRS phantom maintained in the SAD setup by placing the ionization chamber in the lung, bone, and tissue regions, respectively, were acquired. The treatment planning system (TPS) calculated and the ionization chamber measured the doses at the center of the chamber (in the three mediums) were recorded for the flattened and non-flattened photon beams. Results: The results were reported for photon energies of 6 MV, 10 MV, 15 MV, 6 FFF, and 10 FFF of field sizes 5 × 5 cm2, 10 × 10 cm2, and 15 × 15 cm2. In the bone inhomogeneity, the pencil beam algorithm predicted that the maximum dose variation was 4.88% of measured chamber dose in 10-MV photon energy for the field size 10 × 10 cm2. In water inhomogeneity, both the collapsed cone and Monte Carlo algorithm predicted that the maximum dose variation was ± 3% of measured chamber dose in 10-MV photon energy for the field size 10 × 10 cm2 and in 10-MV FFF photon energy for the field size 5 × 5 cm2, whereas in lung inhomogeneity, the pencil beam algorithm predicted that the highest dose variation was - 6.9% of measured chamber dose in 10-MV FFF photon energy for the field size 5 × 5 cm2. Conclusion: FF and FFF beams performed differently in lung, water, and bone mediums. The assessment of algorithms was conducted using the anthropomorphic phantom; therefore, these findings may help in the selection of appropriate algorithms for particular clinical settings in radiation delivery.
Asunto(s)
Aceleradores de Partículas , Radiometría , Humanos , Dosificación Radioterapéutica , Mónaco , Radiometría/métodos , Fotones/uso terapéutico , Planificación de la Radioterapia Asistida por Computador/métodos , Fantasmas de Imagen , AguaRESUMEN
Background: Plastics have conveyed great benefits to humanity and made possible some of the most significant advances of modern civilization in fields as diverse as medicine, electronics, aerospace, construction, food packaging, and sports. It is now clear, however, that plastics are also responsible for significant harms to human health, the economy, and the earth's environment. These harms occur at every stage of the plastic life cycle, from extraction of the coal, oil, and gas that are its main feedstocks through to ultimate disposal into the environment. The extent of these harms not been systematically assessed, their magnitude not fully quantified, and their economic costs not comprehensively counted. Goals: The goals of this Minderoo-Monaco Commission on Plastics and Human Health are to comprehensively examine plastics' impacts across their life cycle on: (1) human health and well-being; (2) the global environment, especially the ocean; (3) the economy; and (4) vulnerable populations-the poor, minorities, and the world's children. On the basis of this examination, the Commission offers science-based recommendations designed to support development of a Global Plastics Treaty, protect human health, and save lives. Report Structure: This Commission report contains seven Sections. Following an Introduction, Section 2 presents a narrative review of the processes involved in plastic production, use, and disposal and notes the hazards to human health and the environment associated with each of these stages. Section 3 describes plastics' impacts on the ocean and notes the potential for plastic in the ocean to enter the marine food web and result in human exposure. Section 4 details plastics' impacts on human health. Section 5 presents a first-order estimate of plastics' health-related economic costs. Section 6 examines the intersection between plastic, social inequity, and environmental injustice. Section 7 presents the Commission's findings and recommendations. Plastics: Plastics are complex, highly heterogeneous, synthetic chemical materials. Over 98% of plastics are produced from fossil carbon- coal, oil and gas. Plastics are comprised of a carbon-based polymer backbone and thousands of additional chemicals that are incorporated into polymers to convey specific properties such as color, flexibility, stability, water repellence, flame retardation, and ultraviolet resistance. Many of these added chemicals are highly toxic. They include carcinogens, neurotoxicants and endocrine disruptors such as phthalates, bisphenols, per- and poly-fluoroalkyl substances (PFAS), brominated flame retardants, and organophosphate flame retardants. They are integral components of plastic and are responsible for many of plastics' harms to human health and the environment.Global plastic production has increased almost exponentially since World War II, and in this time more than 8,300 megatons (Mt) of plastic have been manufactured. Annual production volume has grown from under 2 Mt in 1950 to 460 Mt in 2019, a 230-fold increase, and is on track to triple by 2060. More than half of all plastic ever made has been produced since 2002. Single-use plastics account for 35-40% of current plastic production and represent the most rapidly growing segment of plastic manufacture.Explosive recent growth in plastics production reflects a deliberate pivot by the integrated multinational fossil-carbon corporations that produce coal, oil and gas and that also manufacture plastics. These corporations are reducing their production of fossil fuels and increasing plastics manufacture. The two principal factors responsible for this pivot are decreasing global demand for carbon-based fuels due to increases in 'green' energy, and massive expansion of oil and gas production due to fracking.Plastic manufacture is energy-intensive and contributes significantly to climate change. At present, plastic production is responsible for an estimated 3.7% of global greenhouse gas emissions, more than the contribution of Brazil. This fraction is projected to increase to 4.5% by 2060 if current trends continue unchecked. Plastic Life Cycle: The plastic life cycle has three phases: production, use, and disposal. In production, carbon feedstocks-coal, gas, and oil-are transformed through energy-intensive, catalytic processes into a vast array of products. Plastic use occurs in every aspect of modern life and results in widespread human exposure to the chemicals contained in plastic. Single-use plastics constitute the largest portion of current use, followed by synthetic fibers and construction.Plastic disposal is highly inefficient, with recovery and recycling rates below 10% globally. The result is that an estimated 22 Mt of plastic waste enters the environment each year, much of it single-use plastic and are added to the more than 6 gigatons of plastic waste that have accumulated since 1950. Strategies for disposal of plastic waste include controlled and uncontrolled landfilling, open burning, thermal conversion, and export. Vast quantities of plastic waste are exported each year from high-income to low-income countries, where it accumulates in landfills, pollutes air and water, degrades vital ecosystems, befouls beaches and estuaries, and harms human health-environmental injustice on a global scale. Plastic-laden e-waste is particularly problematic. Environmental Findings: Plastics and plastic-associated chemicals are responsible for widespread pollution. They contaminate aquatic (marine and freshwater), terrestrial, and atmospheric environments globally. The ocean is the ultimate destination for much plastic, and plastics are found throughout the ocean, including coastal regions, the sea surface, the deep sea, and polar sea ice. Many plastics appear to resist breakdown in the ocean and could persist in the global environment for decades. Macro- and micro-plastic particles have been identified in hundreds of marine species in all major taxa, including species consumed by humans. Trophic transfer of microplastic particles and the chemicals within them has been demonstrated. Although microplastic particles themselves (>10 µm) appear not to undergo biomagnification, hydrophobic plastic-associated chemicals bioaccumulate in marine animals and biomagnify in marine food webs. The amounts and fates of smaller microplastic and nanoplastic particles (MNPs <10 µm) in aquatic environments are poorly understood, but the potential for harm is worrying given their mobility in biological systems. Adverse environmental impacts of plastic pollution occur at multiple levels from molecular and biochemical to population and ecosystem. MNP contamination of seafood results in direct, though not well quantified, human exposure to plastics and plastic-associated chemicals. Marine plastic pollution endangers the ocean ecosystems upon which all humanity depends for food, oxygen, livelihood, and well-being. Human Health Findings: Coal miners, oil workers and gas field workers who extract fossil carbon feedstocks for plastic production suffer increased mortality from traumatic injury, coal workers' pneumoconiosis, silicosis, cardiovascular disease, chronic obstructive pulmonary disease, and lung cancer. Plastic production workers are at increased risk of leukemia, lymphoma, hepatic angiosarcoma, brain cancer, breast cancer, mesothelioma, neurotoxic injury, and decreased fertility. Workers producing plastic textiles die of bladder cancer, lung cancer, mesothelioma, and interstitial lung disease at increased rates. Plastic recycling workers have increased rates of cardiovascular disease, toxic metal poisoning, neuropathy, and lung cancer. Residents of "fenceline" communities adjacent to plastic production and waste disposal sites experience increased risks of premature birth, low birth weight, asthma, childhood leukemia, cardiovascular disease, chronic obstructive pulmonary disease, and lung cancer.During use and also in disposal, plastics release toxic chemicals including additives and residual monomers into the environment and into people. National biomonitoring surveys in the USA document population-wide exposures to these chemicals. Plastic additives disrupt endocrine function and increase risk for premature births, neurodevelopmental disorders, male reproductive birth defects, infertility, obesity, cardiovascular disease, renal disease, and cancers. Chemical-laden MNPs formed through the environmental degradation of plastic waste can enter living organisms, including humans. Emerging, albeit still incomplete evidence indicates that MNPs may cause toxicity due to their physical and toxicological effects as well as by acting as vectors that transport toxic chemicals and bacterial pathogens into tissues and cells.Infants in the womb and young children are two populations at particularly high risk of plastic-related health effects. Because of the exquisite sensitivity of early development to hazardous chemicals and children's unique patterns of exposure, plastic-associated exposures are linked to increased risks of prematurity, stillbirth, low birth weight, birth defects of the reproductive organs, neurodevelopmental impairment, impaired lung growth, and childhood cancer. Early-life exposures to plastic-associated chemicals also increase the risk of multiple non-communicable diseases later in life. Economic Findings: Plastic's harms to human health result in significant economic costs. We estimate that in 2015 the health-related costs of plastic production exceeded $250 billion (2015 Int$) globally, and that in the USA alone the health costs of disease and disability caused by the plastic-associated chemicals PBDE, BPA and DEHP exceeded $920 billion (2015 Int$). Plastic production results in greenhouse gas (GHG) emissions equivalent to 1.96 gigatons of carbon dioxide (CO2e) annually. Using the US Environmental Protection Agency's (EPA) social cost of carbonmetric, we estimate the annual costs of these GHG emissions to be $341 billion (2015 Int$).These costs, large as they are, almost certainly underestimate the full economic losses resulting from plastics' negative impacts on human health and the global environment. All of plastics' economic costs-and also its social costs-are externalized by the petrochemical and plastic manufacturing industry and are borne by citizens, taxpayers, and governments in countries around the world without compensation. Social Justice Findings: The adverse effects of plastics and plastic pollution on human health, the economy and the environment are not evenly distributed. They disproportionately affect poor, disempowered, and marginalized populations such as workers, racial and ethnic minorities, "fenceline" communities, Indigenous groups, women, and children, all of whom had little to do with creating the current plastics crisis and lack the political influence or the resources to address it. Plastics' harmful impacts across its life cycle are most keenly felt in the Global South, in small island states, and in disenfranchised areas in the Global North. Social and environmental justice (SEJ) principles require reversal of these inequitable burdens to ensure that no group bears a disproportionate share of plastics' negative impacts and that those who benefit economically from plastic bear their fair share of its currently externalized costs. Conclusions: It is now clear that current patterns of plastic production, use, and disposal are not sustainable and are responsible for significant harms to human health, the environment, and the economy as well as for deep societal injustices.The main driver of these worsening harms is an almost exponential and still accelerating increase in global plastic production. Plastics' harms are further magnified by low rates of recovery and recycling and by the long persistence of plastic waste in the environment.The thousands of chemicals in plastics-monomers, additives, processing agents, and non-intentionally added substances-include amongst their number known human carcinogens, endocrine disruptors, neurotoxicants, and persistent organic pollutants. These chemicals are responsible for many of plastics' known harms to human and planetary health. The chemicals leach out of plastics, enter the environment, cause pollution, and result in human exposure and disease. All efforts to reduce plastics' hazards must address the hazards of plastic-associated chemicals. Recommendations: To protect human and planetary health, especially the health of vulnerable and at-risk populations, and put the world on track to end plastic pollution by 2040, this Commission supports urgent adoption by the world's nations of a strong and comprehensive Global Plastics Treaty in accord with the mandate set forth in the March 2022 resolution of the United Nations Environment Assembly (UNEA).International measures such as a Global Plastics Treaty are needed to curb plastic production and pollution, because the harms to human health and the environment caused by plastics, plastic-associated chemicals and plastic waste transcend national boundaries, are planetary in their scale, and have disproportionate impacts on the health and well-being of people in the world's poorest nations. Effective implementation of the Global Plastics Treaty will require that international action be coordinated and complemented by interventions at the national, regional, and local levels.This Commission urges that a cap on global plastic production with targets, timetables, and national contributions be a central provision of the Global Plastics Treaty. We recommend inclusion of the following additional provisions:The Treaty needs to extend beyond microplastics and marine litter to include all of the many thousands of chemicals incorporated into plastics.The Treaty needs to include a provision banning or severely restricting manufacture and use of unnecessary, avoidable, and problematic plastic items, especially single-use items such as manufactured plastic microbeads.The Treaty needs to include requirements on extended producer responsibility (EPR) that make fossil carbon producers, plastic producers, and the manufacturers of plastic products legally and financially responsible for the safety and end-of-life management of all the materials they produce and sell.The Treaty needs to mandate reductions in the chemical complexity of plastic products; health-protective standards for plastics and plastic additives; a requirement for use of sustainable non-toxic materials; full disclosure of all components; and traceability of components. International cooperation will be essential to implementing and enforcing these standards.The Treaty needs to include SEJ remedies at each stage of the plastic life cycle designed to fill gaps in community knowledge and advance both distributional and procedural equity.This Commission encourages inclusion in the Global Plastic Treaty of a provision calling for exploration of listing at least some plastic polymers as persistent organic pollutants (POPs) under the Stockholm Convention.This Commission encourages a strong interface between the Global Plastics Treaty and the Basel and London Conventions to enhance management of hazardous plastic waste and slow current massive exports of plastic waste into the world's least-developed countries.This Commission recommends the creation of a Permanent Science Policy Advisory Body to guide the Treaty's implementation. The main priorities of this Body would be to guide Member States and other stakeholders in evaluating which solutions are most effective in reducing plastic consumption, enhancing plastic waste recovery and recycling, and curbing the generation of plastic waste. This Body could also assess trade-offs among these solutions and evaluate safer alternatives to current plastics. It could monitor the transnational export of plastic waste. It could coordinate robust oceanic-, land-, and air-based MNP monitoring programs.This Commission recommends urgent investment by national governments in research into solutions to the global plastic crisis. This research will need to determine which solutions are most effective and cost-effective in the context of particular countries and assess the risks and benefits of proposed solutions. Oceanographic and environmental research is needed to better measure concentrations and impacts of plastics <10 µm and understand their distribution and fate in the global environment. Biomedical research is needed to elucidate the human health impacts of plastics, especially MNPs. Summary: This Commission finds that plastics are both a boon to humanity and a stealth threat to human and planetary health. Plastics convey enormous benefits, but current linear patterns of plastic production, use, and disposal that pay little attention to sustainable design or safe materials and a near absence of recovery, reuse, and recycling are responsible for grave harms to health, widespread environmental damage, great economic costs, and deep societal injustices. These harms are rapidly worsening.While there remain gaps in knowledge about plastics' harms and uncertainties about their full magnitude, the evidence available today demonstrates unequivocally that these impacts are great and that they will increase in severity in the absence of urgent and effective intervention at global scale. Manufacture and use of essential plastics may continue. However, reckless increases in plastic production, and especially increases in the manufacture of an ever-increasing array of unnecessary single-use plastic products, need to be curbed.Global intervention against the plastic crisis is needed now because the costs of failure to act will be immense.
Asunto(s)
Enfermedades Cardiovasculares , Disruptores Endocrinos , Retardadores de Llama , Gases de Efecto Invernadero , Neoplasias Pulmonares , Enfermedad Pulmonar Obstructiva Crónica , Estados Unidos , Niño , Animales , Humanos , Masculino , Femenino , Preescolar , Plásticos/toxicidad , Plásticos/química , Ecosistema , Mónaco , Microplásticos , Contaminantes Orgánicos Persistentes , Disruptores Endocrinos/toxicidad , Carbón MineralRESUMEN
Aim: The purpose of this clinical study was to analyze the clinical feasibility of friction fit conical abutment system in implant-supported fixed dental prostheses as an alternative to cement and screw retention. Settings and Design: This was an in vivo longitudinal study. Materials and Methods: A total of 10 prostheses were designed as 3- or 4-unit fixed dental prostheses supported by two implants. All the subjects selected were evaluated for pocket probing depth (PPD) and marginal bone loss at the time of implant placement (T1), at the time of placement of friction fit prostheses (T2), and 12 months after placement of friction fit prostheses (T3). Marginal bone loss at T2 and T3 was measured with respect to bone levels at T1 and T2, respectively. The patient satisfaction was assessed at T2 and T3 using FDI clinical criteria and scoring system (modified by Monaco et al.). Statistical Analysis Used: Shapiro-Wilk test was employed to test the normality of data. Paired sample t-test was performed for quantitative variables. Results: A total of twenty implants were inserted in ten partially edentulous spaces; the average patient age was 50.2 years. No significant difference was seen between T2 and T3 for PPD. Comparison of marginal bone loss using paired t-test showed a statistically highly significant difference at T2 and T3 with higher value at T2. No prostheses were dislodged during postprosthetic follow-up. The survival rate was 100% for both the abutments and implants. No change in surface luster was observed 12 months following prosthetic rehabilitation in any case. No prostheses or framework fracture was reported and all patients were satisfied with the prosthesis received. Conclusions: Friction fit conical abutment system can act as a novel approach for the retention of implant-supported fixed dental prostheses.
Asunto(s)
Implantes Dentales , Boca Edéntula , Humanos , Persona de Mediana Edad , Prótesis Dental de Soporte Implantado/efectos adversos , Implantes Dentales/efectos adversos , Estudios Longitudinales , MónacoRESUMEN
BACKGROUND: To date, no curative treatment is available for Alzheimer's disease (AD). Therefore, efforts should focus on prevention strategies to improve the efficiency of healthcare systems. OBJECTIVE: Our aim was to assess the cost-effectiveness of three preventive strategies for AD compared to a placebo. DESIGN: The Multidomain Alzheimer Preventive Trial (MAPT) study was a multicenter, randomized, placebo-controlled superiority trial with four parallel groups, including three intervention groups (one group with Multidomain Intervention (MI) plus a placebo, one group with Polyunsaturated Fatty Acids (PFA), one group with a combination of PFA and MI) and one placebo group. SETTING: Participants were recruited and included in 13 memory centers in France and Monaco. PARTICIPANTS: Community-dwelling subject aged 70 years and older were followed during 3 years. INTERVENTIONS: We used data from the MAPT study which aims to test the efficacy of a MI along PFA, the MI plus a placebo, PFA alone, or a placebo alone. MEASUREMENT: Direct medical and non-medical costs were calculated from a payer's perspective during the 3 years of follow-up. The base case incremental Cost-Effectiveness Ratio (ICER) represents the cost per improved cognitive Z-score point. Sensitivity analyses were performed using different interpretation of the effectiveness criteria. RESULTS: Analyses were conducted on 1,525 participants. The ICER at year 3 that compares the MI + PFA and the MI alone to the placebo amounted to 21,443 and 21,543 respectively, per improved Z score point. PFA alone amounted to 111,720 per improved Z score point. CONCLUSION: Our study shows that ICERS of PFA combined with MI and MI alone amounted to 21,443 and 21,543 respectively per improved Z score point compared to the placebo and are below the WTP of 50,000 while the ICER of PFA alone amounted to 111,720 per improved Z score point. This information may help decision makers and serve as a basis for the implementation of a lifetime decision analytic model.
Asunto(s)
Enfermedad de Alzheimer , Cognición/fisiología , Análisis Costo-Beneficio/economía , Ácidos Docosahexaenoicos/administración & dosificación , Ejercicio Físico/fisiología , Anciano , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/prevención & control , Femenino , Francia , Humanos , Vida Independiente , Masculino , Mónaco , Proyectos de InvestigaciónRESUMEN
PURPOSE: In this study, 4-Hz log files were evaluated with an independent secondary Monte Carlo dose calculation algorithm to reduce the workload for patient-specific quality assurance (QA) in clinical routine. MATERIALS AND METHODS: A total of 30 randomly selected clinical prostate VMAT plans were included. The used treatment planning system (TPS) was Monaco (Elekta, Crawley), and the secondary dose calculation software was SciMoCa (Scientific-RT, Munich). Monaco and SciMoCa work with a Monte Carlo algorithm. A plausibility check of Monaco and SciMoCa was performed using an ionization chamber in the BodyPhantom (BP). First, the original Monaco RT plans were verified with SciMoCa (pretreatment QA). Second, the corresponding 4-Hz log files were converted into RT log file plans and sent to SciMoCa as on-treatment QA. MLC shift errors were introduced for one prostate plan to determine the sensitivity of on-treatment QA. For pretreatment and on-treatment QA, a gamma analysis (2%/1mm/20%) was performed and dosimetric values of PTV and OARs were ascertained in SciMoCa. RESULTS: Plausibility check of TPS Monaco vs. BP measurement and SciMoCa vs. BP measurement showed valid accuracy for clinical VMAT QA. Using SciMoCa, there was no significant difference in PTV Dmean between RT plan and RT log file plan. Between pretreatment and on-treatment QA, PTV metrics, femur right and left showed no significant dosimetric differences as opposed to OARs rectum and bladder. The overall gamma passing rate (GPR) ranged from 96.10% to 100% in pretreatment QA and from 93.50% to 99.80% in on-treatment QA. MLC shift errors were identified for deviations larger than -0.50 mm and +0.75 mm using overall gamma criterion and PTV Dmean. CONCLUSION: SciMoCa calculations of Monaco RT plans and RT log file plans are in excellent agreement to each other. Therefore, 4-Hz log files and SciMoCa can replace labor-intensive phantom-based measurements as patient-specific QA.
Asunto(s)
Próstata , Radioterapia de Intensidad Modulada , Humanos , Masculino , Mónaco , Garantía de la Calidad de Atención de Salud , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
BACKGROUND: Complete atrioventricular block (AVB3) may be an urgent potentially lifethreatening situation. Our objective was to describe the routine management of AVB 3, with emphasis on the organizational aspects. METHODS: From September 2019 to November 2019, a prospective national survey including 28 questions was electronically sent to 100 physicians (Google Form). RESULTS: The answers were collected from 93 physicians (response rate 93%). Permanent pacemaker implantation during weekends and nights (after 8PM) is possible for 49% of the operators (<5 times a year), for 15% (>5 times a year), impossible for 36% of the operators. For AVB3 nonresponsive to isoproterenol occurring during the night, a temporary pacing lead (TPL) is implanted by: the on-site medical staff on-duty (27%), the on-call interventional cardiologist (21%), the on-call electrophysiologist (19%), a permanent pacemaker is implanted by the electrophysiologist (12%), the strategy is not standardized (15%). An externalized active fixation lead (AFL) for AVB3 has already been implanted by 50% of the operators. 80 (86%) have already observed a dislocation of the TPL, a cardiac perforation already occurred in 57 (61%), a groin hematoma in 35 (38%), and this technique was proscribed for 4% of the operators. CONCLUSION: Our survey shows important disparities in terms of management of AVB3 among the different centers. An externalized AFL with a reusable generator was used by half of the centers.
Asunto(s)
Atención Posterior/organización & administración , Bloqueo Atrioventricular/terapia , Encuestas de Atención de la Salud , Marcapaso Artificial , Adulto , Atención Posterior/estadística & datos numéricos , Anciano , Argelia , Cardiotónicos/uso terapéutico , Resistencia a Medicamentos , Francia , Lesiones Cardíacas/epidemiología , Hematoma/epidemiología , Humanos , Isoproterenol/uso terapéutico , Malí , Persona de Mediana Edad , Mónaco , Marruecos , Marcapaso Artificial/efectos adversos , Estudios Prospectivos , Implantación de Prótesis/efectos adversos , Implantación de Prótesis/métodos , TúnezRESUMEN
PURPOSE: Patient-specific quality assurance (QA) is very important in radiotherapy, especially for patients with highly conformed treatment plans like VMAT plans. Traditional QA protocols for these plans are time-consuming reducing considerably the time available for patient treatments. In this work, a new MC-based secondary dose check software (SciMoCa) is evaluated and benchmarked against well-established TPS (Monaco and Pinnacle3 ) by means of treatment plans and dose measurements. METHODS: Fifty VMAT plans have been computed using same calculation parameters with SciMoCa and the two primary TPSs. Plans were validated with measurements performed with a 3D diode detector (ArcCHECK) by translating patient plans to phantom geometry. Calculation accuracy was assessed by measuring point dose differences and gamma passing rates (GPR) from a 3D gamma analysis with 3%-2 mm criteria. Comparison between SciMoCa and primary TPS calculations was made using the same estimators and using both patient and phantom geometry plans. RESULTS: TPS and SciMoCa calculations were found to be in very good agreement with validation measurements with average point dose differences of 0.7 ± 1.7% and -0.2 ± 1.6% for SciMoCa and two TPSs, respectively. Comparison between SciMoCa calculations and the two primary TPS plans did not show any statistically significant difference with average point dose differences compatible with zero within error for both patient and phantom geometry plans and GPR (98.0 ± 3.0% and 99.0 ± 3.0% respectively) well in excess of the typical 95 % clinical tolerance threshold. CONCLUSION: This work presents results obtained with a significantly larger sample than other similar analyses and, to the authors' knowledge, compares SciMoCa with a MC-based TPS for the first time. Results show that a MC-based secondary patient-specific QA is a clinically viable, reliable, and promising technique, that potentially allows significant time saving that can be used for patient treatment and a per-plan basis QA that effectively complements traditional commissioning and calibration protocols.
Asunto(s)
Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada , Algoritmos , Humanos , Mónaco , Método de Montecarlo , Fantasmas de Imagen , Garantía de la Calidad de Atención de Salud , Dosificación RadioterapéuticaRESUMEN
In a mixed-vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Eclipse are discussed. In each TPS static field, Intensity-Modulated Radiation Therapy (IMRT) step and shoot, and Volumetric-Modulated Arc Therapy (VMAT) plans for flattened and flattening-filter free photon beams of all available energies were evaluated for field sizes >3 × 3. To compare passing rates, identical beam model validation plans were calculated in each TPS. Eclipse, Monaco, and Pinnacle beam models passed validation measurements in homogeneous materials for a variety of treatment fields, including static, IMRT, and VMAT. In the case of Eclipse, the "dosimetric leaf gap" parameter was found to be critical for passing rates of VMAT plans. The source size parameter plays an important role as well for small fields. In the case of Pinnacle the multileaf collimator offset table needed to be optimized for better VMAT QA results. Each of the investigated treatment planning systems met the criteria to be used clinically in conjunction with Elekta Versa HD linear accelerators. It can be of great advantage to have the option to operate a TPS and linear accelerator from different vendors, as decisions surrounding linear accelerator or TPS purchases are very complicated and not just limited to technical considerations.
Asunto(s)
Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada , Humanos , Mónaco , Aceleradores de Partículas , Radiometría , Dosificación RadioterapéuticaRESUMEN
BACKGROUND/OBJECTIVES: Cognitive decline associated with impaired kidney function might involve neurodegeneration. Our objectives were to evaluate the longitudinal association between kidney function and cognitive decline in older adults and to assess the involvement of cortical beta-amyloid and hippocampal atrophy (features of Alzheimer's disease (AD)) in this association. DESIGN: Secondary analysis of the randomized controlled Multidomain Alzheimer Preventive Trial (MAPT). SETTINGS: Thirteen memory centers (France and Monaco, 2008-2016). PARTICIPANTS: A total of 1,334 community-dwellers >70 years old without dementia at baseline. MEASUREMENTS: We estimated glomerular filtration rate (eGFR) from serum creatinine using CKD-Epi equation. Cognition was assessed at baseline, 6, 12, 24, 36, 48, and 60 months using a composite Z-score designed for MAPT. The Clinical Dementia Rating (CDR) score was used to assess cognition and functional independence. We examined the association between eGFR and (1) evolution of the composite cognitive Z-score using mixed-effect models and (2) progression on CDR using Cox models and mixed-effect models. Adjustments were made for age, sex, education, ApoE genotype, cardiovascular risk factors and disease, hippocampal volume (measured with magnetic resonance), and cortical beta-amyloid (measured with positron emission tomography). RESULTS: Median (IQR) eGFR was 73(60-84) mL/min/1.73 m2 . Two hundred sixty-nine participants experienced progression on CDR score during follow-up. eGFR<60 was significantly associated with progression on CDR score (adjusted hazard ratio (aHR) = 1.35, 95% CI 1.01-1.80) and with both the cognitive and functional independence components of CDR, but not with the evolution of the composite cognitive Z-score (adjusted ß-coefficient -0.004, 95% CI -0.014; 0.006). Associations were not modified after further adjustment for beta-amyloid (subsample: n = 252) and hippocampal volume (subsample: n = 270). CONCLUSIONS: We did not find a mild to moderate renal insufficiency to be associated with brain imaging features of AD, and our results do not support the involvement of AD mechanisms in the incidence of cognitive impairment and functional decline associated with chronic kidney disease.
Asunto(s)
Actividades Cotidianas , Disfunción Cognitiva/etiología , Insuficiencia Renal/complicaciones , Anciano , Péptidos beta-Amiloides/metabolismo , Biomarcadores/análisis , Disfunción Cognitiva/diagnóstico , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Francia , Tasa de Filtración Glomerular/fisiología , Humanos , Masculino , MónacoRESUMEN
Monte Carlo (MC)-based treatment planning requires a choice of dose voxel size (DVS) and statistical uncertainty (SU). These parameters effect both the precision of displayed dose distribution and time taken to complete a calculation. For efficient, accurate, and precise treatment planning in a clinical setting, optimal values should be selected. In this investigation, 30 volumetric modulated arc therapy (VMAT) stereotactic radiotherapy (SRT) treatment plans, 10 brain, 10 lung, and 10 spine were calculated in the Monaco 5.11.02 treatment planning system (TPS). Each plan was calculated with a DVS of 0.1 and 0.2 cm using SU values of 0.50%, 0.75%, 1.00%, 1.50%, and 2.00%, along with a ground truth calculation using a DVS of 0.1 cm and SU of 0.15%. The variance at each relative dose level was calculated for all SU settings to assess their relationship. The variation from the ground truth calculation for each DVS and SU combination was determined for a range of DVH metrics and plan quality indices along with the time taken to complete the calculations. Finally, the effect of defining the maximum dose using a volume of 0.035 cc was compared to 0.100 cc when considering DVS and SU settings. Changes in the DVS produced greater variations from the ground truth calculation than changes in SU across the values tested. Plan quality metrics and mean dose values showed less sensitivity to changes in SU than DVH metrics. From this study, it was concluded that while maintaining an average calculation time of <10 min, 75% of plans could be calculated with variations of <2.0% from their ground truth values when using an SU setting of 1.50% and a DVS of 0.1 cm in the case of brain or spine plans, and a 0.2 cm DVS in the case of lung plans.
Asunto(s)
Radiocirugia , Radioterapia de Intensidad Modulada , Humanos , Mónaco , Método de Montecarlo , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por Computador , IncertidumbreRESUMEN
PURPOSE: This study evaluates the clinical use of the RUBY modular QA phantom for linac QA to validate the integrity of IGRT workflows including the congruence of machine isocenter, imaging isocenter, and room lasers. The results have been benchmarked against those obtained with widely used systems. Additionally, the RUBY phantom has been implemented to perform system QA (End-to-End testing) from imaging to radiation for IGRT-based VMAT and stereotactic radiations at an Elekta Synergy linac. MATERIAL AND METHODS: The daily check of IGRT workflow was performed using the RUBY phantom, the Penta-Guide, and the STEEV phantom. Furthermore, Winston-Lutz tests was carried out with the RUBY phantom and a ball-bearing phantom to determine the offsets and the diameters of the isospheres of gantry, collimator, and couch rotations, with respect to the room lasers and kV-imaging isocenter. System QA was performed with the RUBY phantom and STEEV phantom for eight VMAT treatment plans. Additionally, the visibility of the embedded objects within these phantoms in the images and the results of CT and MR image fusions were evaluated. RESULTS: All systems used for daily QA of IGRT workflows show comparable results. Calculated shifts based on CBCT imaging agree within 1 mm to the expected values. The results of the Winston-Lutz test based on kV imaging (2D planar and CBCT) or room lasers are consistent regardless of the system tested. The point dose values in the RUBY phantom agree to the expected values calculated using algorithms in Masterplan and Monte Carlo engine in Monaco within 3% of the clinical acceptance criteria. CONCLUSION: All the systems evaluated in this study yielded comparable results in terms of linac QA and system QA procedures. A system QA protocol has been derived using the RUBY phantom to check the IGRT-based VMAT and stereotactic radiations workflow at an Elekta Synergy linac.
Asunto(s)
Radiocirugia , Humanos , Mónaco , Aceleradores de Partículas , Fantasmas de Imagen , Garantía de la Calidad de Atención de SaludAsunto(s)
COVID-19/prevención & control , Servicio de Cardiología en Hospital/tendencias , Enfermedades Cardiovasculares/terapia , Servicio de Urgencia en Hospital/tendencias , Admisión del Paciente/tendencias , Aislamiento Social , COVID-19/epidemiología , COVID-19/transmisión , Enfermedades Cardiovasculares/diagnóstico , Accesibilidad a los Servicios de Salud/tendencias , Humanos , Mónaco , Aceptación de la Atención de Salud , Estudios Retrospectivos , Factores de TiempoRESUMEN
PURPOSE: The purpose of this study was to develop an auto-planning platform to be interfaced with a commercial treatment planning system (TPS). The main goal was to obtain robust and high-quality plans for different anatomic sites and various dosimetric requirements. METHODS: Monaco (Elekta, St. Louis, US) was the TPS in this work. All input parameters for inverse planning could be defined in a plan template inside Monaco. A software tool called Robot Framework was used to launch auto-planning trials with updated plan templates. The template modifier external to Monaco was the major component of our auto-planning platform. For current implementation, it was a rule-based system that mimics the trial-and-error process of an experienced planner. A template was automatically updated by changing the optimization constraints based on dosimetric evaluation of the plan obtained in the previous trial, along with the data of the iterative optimization extracted from Monaco. Treatment plans generated by Monaco with all plan evaluation criteria satisfied were considered acceptable, and such plans would be saved for further evaluation by clinicians. The auto-planning platform was validated for 10 prostate and 10 head-and-neck cases in comparison with clinical plans generated by experienced planners. RESULTS: The performance and robustness of our auto-planning platform was tested with clinical cases of prostate and head and neck treatment. For prostate cases, automatically generated plans had very similar plan quality with the clinical plans, and the bladder volume receiving 62.5 Gy, 50 Gy, and 40 Gy in auto-plans was reduced by 1%, 3%, and 5%, respectively. For head and neck cases, auto-plans had better conformity with reduced dose to the normal structures but slightly higher dose inhomogeneity in the target volume. Remarkably, the maximum dose in the spinal cord and brain stem was reduced by more than 3.5 Gy in auto-plans. Fluence map optimization only with less than 30 trials was adequate to generate acceptable plans, and subsequent optimization for final plans was completed by Monaco without further intervention. The plan quality was weakly dependent on the parameter selection in the initial template and the choices of the step sizes for changing the constraint values. CONCLUSION: An automated planning platform to interface with Monaco was developed, and our reported tests showed preliminary results for prostate and head and neck cases.
Asunto(s)
Neoplasias de la Próstata , Radioterapia de Intensidad Modulada , Automatización , Humanos , Masculino , Mónaco , Neoplasias de la Próstata/radioterapia , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
In February 2004, anthropogenic radionuclides (137Cs, 236U, 239Pu and 240Pu), transported from the Sahara Desert, were observed in the Monaco air, and later in water and sediment samples collected at the DYFAMED site in the northwest (NW) Mediterranean Sea. While 236U and 137Cs in Saharan dust particles showed a high solubility in seawater, Pu isotopes were particle reactive in the water column and in the sediment. The impact of the Saharan deposition was found at 0-1.0 cm of the sediment core for 236U and 137Cs, and between 1.0 and 1.5 cm for Pu isotopes. The excess of 236U was observed more in the water column than in the sediment, whereas the 239+240Pu total inventories were comparable in the water column and the sediment. This single-day particle event represented 72% of annual atmospheric deposition in Monaco. At the DYFAMED site, it accounted for 10% (137Cs) and 15% (239+240Pu) activities of sinking particles during the period of the highest mass flux collected at the 200 and 1000 m water depths, and for a significant proportion of the total annual atmospheric input to the NW Mediterranean Sea (28-37% for 137Cs and 34-45% for 239+240Pu). Contributions to the total 137Cs and 239+240Pu sediment inventories were estimated to be 14% and 8%, respectively. The Saharan dust deposition phenomenon (atmospheric input, water column and sediment) offered a unique case to study origin and accumulation rates of radionuclides in the NW Mediterranean Sea.
Asunto(s)
Monitoreo de Radiación , Agua de Mar , África del Norte , Atmósfera , Polvo , Sedimentos Geológicos , Mar Mediterráneo , Mónaco , Contaminantes Radiactivos del AguaRESUMEN
BACKGROUND: Whether cavotricuspid isthmus (CTI) is a region of conduction slowing during typical flutter has been discussed with conflicting results in the literature. We aimed to evaluate conduction velocity (CV) along the different portions of the typical flutter circuit with a recently proposed method by means of ultra-high-resolution (UHR) mapping. METHODS: Consecutive patients referred for typical atrial flutter (AFL) ablation underwent UHR mapping (Rhythmia, Boston Scientific). CVs were measured in the CTI as well as laterally and septally, respectively, from its lateral and septal borders. RESULTS: A total of 33 patients (mean age: 65 ± 13 years; right atrial volume: 134 ± 57 mL) were mapped either during ongoing counterclockwise (n = 25), or clockwise (n = 3) AFL (mean cycle length: 264 ± 38 ms), or during coronary sinus pacing at 400 ms (n = 1), 500 ms (n = 1), or 600 ms (n = 3). A total of 13 671 ± 7264 electrograms were acquired in 14 ± 9 min. CTI CV was significantly lower (0.56 ± 0.18 m/s) in comparison with the lateral CV (1.31 ± 0.29 m/s; P < .0001) and the septal border CV of the CTI (1.29 ± 0.31 m/s; P < .0001). CONCLUSION: UHR mapping confirmed that CTI CV was systematically twice lower than atrial conduction velocities outside the CTI.
Asunto(s)
Aleteo Atrial/fisiopatología , Sistema de Conducción Cardíaco/fisiopatología , Válvula Tricúspide/fisiopatología , Anciano , Aleteo Atrial/cirugía , Mapeo del Potencial de Superficie Corporal , Estimulación Cardíaca Artificial , Ablación por Catéter , Electrocardiografía , Femenino , Humanos , Masculino , MónacoAsunto(s)
Biología/organización & administración , Técnicas de Laboratorio Clínico , Sociedades Científicas/organización & administración , Biología/métodos , Biología/tendencias , Técnicas de Laboratorio Clínico/métodos , Técnicas de Laboratorio Clínico/tendencias , Congresos como Asunto , Francia , Humanos , Cooperación Internacional , Lenguaje , Mónaco , Sociedades Científicas/tendenciasRESUMEN
OBJECTIVES: To assess the associations of long-term lifestyle multidomain intervention (MI) and omega-3 supplementation with frailty level evolution and frailty incidence in community-dwelling older persons. DESIGN: Secondary analysis of the randomized controlled Multidomain Alzheimer Preventive Trial. SETTING: Thirteen memory centers in France and Monaco between 2008 and 2011. PARTICIPANTS: A total of 1588 community-dwelling persons aged 70 years or older with memory complaints (without dementia), slow gait speed, or limitation in one instrumental activity of daily living. INTERVENTION: A 3-year MI (43 group sessions including cognitive training, physical activity, and nutrition advice and three preventive consultations) plus daily omega-3 fatty acids, MI plus placebo, omega-3 alone, or placebo alone. MEASUREMENTS: The frailty phenotype (unintentional weight loss, exhaustion, low physical activity, slow gait, low handgrip strength: 0 to 5 score, higher is worse; a score of 3 or higher defines frailty) was assessed at baseline, 6, 12, 24, and 36 months. We used mixed-effect models for frailty level (0-5 score as an ordinal variable) and Cox models for frailty incidence. RESULTS: No differences were found between the intervention groups and placebo on the 3-year evolution of frailty level. Among 1394 non-frail participants at baseline, frailty incidence occurred in 134 (9.6%) persons: 26 (7.6%) in the MI plus omega-3 group, 34 (10%) in the omega-3 alone group, 31 (8.5%) in the MI plus placebo group, and 43 (12.3%) in the placebo-alone group). No differences regarding frailty incidence were found between intervention groups and placebo. After exclusion of 53 participants with incident frailty during the first year of follow-up, MI plus omega-3 was associated with a lower frailty incidence compared with placebo (hazard ratio = .43; 95% confidence interval = .22-.81). CONCLUSION: In community-dwelling older persons, the combination of a long-term lifestyle MI and omega-3 supplementation did not reduce frailty level or incidence. The reduction of frailty incidence associated with the combined intervention in a sensitivity analysis needs to be further confirmed. J Am Geriatr Soc 67:1700-1706, 2019.